Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftobiprole for Mycobacterium abscessus Lung Disease (Shenzhen Third People's Hospital)
ChiCTR2500108292Phase 2Recruiting
- Sponsor
- Shenzhen Third People's Hospital
- Start
- Jun 2025
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ceftobiprole medocaril in Mycobacterium abscessus lung disease (4 arms), sponsored by Shenzhen Third People's Hospital. Primary endpoints: Early bactericidal activity and Time to negative conversion of acid-fast bacilli smear and mycobacterial culture. Started Jun 2025; status: recruiting.
02
Drugs
ceftobiprole medocaril
03
Conditions
Mycobacterium abscessus lung disease
Beyond the preview
Go deeper on ChiCTR2500108292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108292.